In the rapid development of cancer immunotherapy, interleukin 10 (IL-10), as an anti-inflammatory cytokine, has gradually attracted widespread attention in the scientific community. The function of IL-10 is not limited to regulating immune responses, but may have a profound impact on tumor progression and treatment.
IL-10 is primarily produced by monocytes and certain lymphocytes and targets multiple immune system components, including inhibiting the release of pro-inflammatory cytokines. This effect allows IL-10 to play a dual role in the tumor microenvironment, inhibiting inflammatory responses while also promoting tumor growth or metastasis in some cases.
IL-10 was initially known for its ability to inhibit cytokine secretion, antigen presentation, and CD4+ T cell activation. Now, more studies have revealed the immunostimulatory capacity of IL-10 in tumor immunity.
IL-10 is a cytokine encoded by the IL10 gene in humans. This cytokine exerts its effects through the IL-10 receptor complex, primarily on monocytes and certain T and B cells. IL-10 is normally released upon activation of the immune system, and its expression is subject to multiple regulatory mechanisms, including transcriptional and post-transcriptional regulation.
The down-regulation of IL-10 enables it to inhibit Th1 cell cytokines and reduce the expression of MHC II antigens and co-stimulatory molecules in macrophages.
Scientific research has shown that IL-10 has an anti-tumor effect in mouse tumor models. Using genetically modified mice or by overexpressing IL-10 in tumor cells, the researchers found that the growth of primary tumors was inhibited and the metastatic burden was reduced. In particular, the application of PEGylated recombinant IL-10 (PEG-rHuIL-10) has been shown to promote anti-tumor immunity of CD8+ T cells.
After PEG-rHuIL-10 treatment, the patient's CD8+ T cells showed obvious activation markers, suggesting that IL-10 has the potential to promote immunity rather than just suppress it.
To date, many clinical trials have explored the application of IL-10 in the treatment of autoimmune diseases and cancer. Although some trials failed to achieve the expected results, PEG-rHuIL-10 has shown the potential to promote anti-tumor immunity in tumor immunotherapy. Currently, PEG-rHuIL-10 is undergoing phase 3 clinical trials, which indicates that the application of IL-10 in this field is still promising.
The role of IL-10 in tumor immunity is becoming increasingly complex, and future studies will help us understand how this cytokine coordinates the immune response to fight cancer. Can such a powerful immunomodulator become the key to cancer treatment?